Five law firms counselled parties involved in the HKD1.36 billion (USD174 million) listing of innovative biomedicine company Kelun-Biotech Pharmaceutical in Hong Kong.
Kirkland & Ellis, King & Wood Mallesons and Global Law Office advised Kelun-Biotech on the IPO. Partner Lu Mengyu led the Kirkland team providing counsel on Hong Kong and US law.
The King & Wood team advised Kelun-Biotech on PRC law, including counsel Wang Jianping and Yang Wei, and partners Sun Ji and Liu Feng. Global advised on PRC intellectual property law, with partners Jack Li, Ma Degang and Yao Zhengyang leading the team.
Sullivan & Cromwell assisted the joint sponsors Goldman Sachs and CITIC Securities, providing Hong Kong and US law advice. Zhong Lun Law Firm partners Chen Yiwen, Wen Zexiong and Liu Jia advised the joint sponsors on Chinese legal matters.
Kelun-Biotech is the largest biomedicine IPO through chapter 18A of the Hong Kong Listing Rules since 2022, which allows such firms without revenue or profits to debut.
